Trial reportThe American journal of gastroenterology2014
Prucalopride improves bowel function and colonic transit time in patients with chronic constipation: an integrated analysis.
Trial report in The American journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 34 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Double-Blind, Placebo-Controlled, Dose-Finding Trial to Evaluate the Efficacy and Safety of Prucalopride (R093877) in Subjects With Chronic Idiopathic Constipation
A Double-Blind Placebo-Controlled Dose-Finding Trial to Evaluate the Efficacy and Safety of R093877 in Patients With Chronic Idiopathic Constipation
A Double-Blind Placebo-Controlled Dose-Finding Trial to Evaluate the Efficacy and Safety of R093877 in Patients With Chronic Idiopathic Constipation
Who cites it
34 citing papers in PubMed, 6 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- European Consensus on Functional Bloating and Abdominal Distension-An ESNM/UEG Recommendations for Clinical Management.United European gastroenterology journal · 2025Guideline
- Network meta-analysis of probiotics, prebiotics, and synbiotics for the treatment of chronic constipation in adults.European journal of nutrition · 2024Pooled it
- Efficacy and Safety of Probiotics in Geriatric Patients with Constipation: Systematic Review and Meta-Analysis.The journal of nutrition, health & aging · 2023Pooled it
- Efficacy and Tolerability of Prucalopride in Bowel Preparation for Colonoscopy: A Systematic Review and Meta-Analysis.Advances in therapy · 2020Pooled it
- Use of Prucalopride for Chronic Constipation: A Systematic Review and Meta-analysis of Published Randomized, Controlled Trials.Journal of neurogastroenterology and motility · 2016Pooled it
- Trans-anal irrigation therapy to treat adult chronic functional constipation: systematic review and meta-analysis.BMC gastroenterology · 2015Pooled it
- YH12852, a Potent and Selective Receptor Agonist of 5-hydroxytryptamine, Increased Gastrointestinal Motility in Healthy Volunteers and Patients With Functional Constipation.Clinical and translational science · 2021Trial
- Short-Term Daily Intake of Polydextrose Fiber Does Not Shorten Intestinal Transit Time in Constipated Adults: A Randomized Controlled Trial.Nutrients · 2018Trial
- Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study.Arthritis research & therapy · 2017Trial
- Fecal microbiota transplantation in patients with slow-transit constipation: A randomized, clinical trial.PloS one · 2017Trial
- Effect and safety of deep needling and shallow needling for functional constipation: a multicenter, randomized controlled trial.Medicine · 2014Trial
- Colon Capsule Endoscopy-Measured Colonic Transit Time Is Associated with Frailty in Older Adults.Medicina (Kaunas, Lithuania) · 2026Article
- Pathophysiological mechanisms, diagnostic innovations, and multimodal therapeutic strategies for slow transit constipation.BMC gastroenterology · 2025Review
- Tissue distribution and abuse potential of prucalopride: findings from non-clinical and clinical studies.Drugs in context · 2023Article
- A Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of DA-9701 (Motilitone) in Patients With Constipation-type Irritable Bowel Syndrome and Functional Dyspepsia Overlap: A Pilot Study.Journal of neurogastroenterology and motility · 2022Article
- Effects of Automatic Abdominal Massage Device in Treatment of Chronic Constipation Patients: A Prospective Study.Digestive diseases and sciences · 2021Article
- Analysis of Gut Microbiome and Metabolite Characteristics in Patients with Slow Transit Constipation.Digestive diseases and sciences · 2021Observational
- Gut Metagenome as a Potential Diagnostic and Predictive Biomarker in Slow Transit Constipation.Frontiers in medicine · 2021Article
- Bowel Dysfunction in Spinal Cord Injury.Current gastroenterology reports · 2018Review
- Prucalopride Inhibits Proliferation of Ovarian Cancer Cells via Phosphatidylinositol 3-Kinase (PI3K) Signaling Pathway.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesConstipation is often characterized by slow colonic transit, but the relationship between colonic transit time (CTT) and symptoms is unclear. The aims of this study were to investigate the effect of prucalopride, a 5-hydroxytryptamine receptor-4 agonist, on CTT and assess the relationship between CTT and symptoms.
methodsThis was an integrated analysis of three randomized, placebo-controlled, phase 2 dose-finding trials of prucalopride in patients with chronic constipation (ClinicalTrials.gov identifiers: NCT00617513; NCT00631813; and NCT00596596). Measurements of CTT were analyzed using radio-opaque markers at the start and end (4 or 12 weeks) of treatment. At these visits, patients assessed the presence and severity of their symptoms.
resultsIn total, 280 patients had CTT measurements before and at the end of treatment and were included in the analysis. Their mean age was 43 years, 93% were women, and mean duration of constipation was 19 years. After a once daily treatment with prucalopride 2 mg (n=98) and 4 mg (n=70), CTT was reduced by 12.0 h (95% confidence interval (CI): -18.9, -5.1) and 13.9 h (95% CI: -20.5, -7.4), respectively; CTT increased by 0.5 h (95% CI: -4.5, 5.5) with placebo (n=112). At the end of the trial, symptoms including bloating/flatulence/distension and straining were rated as severe or very severe by a higher proportion of patients with slow or very slow CTT (>48 h) than by those with normal CTT.
conclusionsThere was a clear relationship between increased CTT and increased symptom severity in patients with chronic constipation. Treatment with prucalopride accelerated CTT in these individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.